<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Substance use disorders: Clinical assessment</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Substance use disorders: Clinical assessment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Substance use disorders: Clinical assessment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karen L Dugosh, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John S Cacciola, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew J Saxon, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Friedman, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 25, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H561606501"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Substance use disorders (SUDs) are highly prevalent. According to a United States national survey, approximately 14.5 percent of individuals age 12 or over had a diagnosable SUD in the past year, including approximately 10.2 percent with an alcohol use disorder and 6.6 percent with an illicit drug use disorder [<a href="#rid1">1</a>]. Illicit drug use and nonmedical use of medications alone or in combination with alcohol are associated with a substantial proportion of emergency department visits in the United States [<a href="#rid2">2,3</a>]. The United States Centers for Disease Control and Prevention's National Center for Health Statistics estimated that there were 105,752 overdose deaths in the 12-month period ending October 2021 [<a href="#rid4">4</a>].</p><p>A thorough substance use assessment includes a detailed inventory of the type, amount, frequency, and consequences of the patient's substance use, their perception of their use, and readiness to change. Additionally, we review past medical and psychiatric history and assess for co-occurring psychiatric disorders. We review family history and psychosocial factors that may contribute to substance use or facilitate treatment. We do a general physical examination and order laboratory tests as indicated.</p><p>The clinical assessment of substance use disorders is reviewed here. Screening for substance use is reviewed separately. The clinical presentation and diagnosis of SUDs specific to individual classes of substances are also reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14843.html" rel="external">"Screening for unhealthy use of alcohol and other drugs in primary care"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7809.html" rel="external">"Risky drinking and alcohol use disorder: Epidemiology, clinical features, adverse consequences, screening, and assessment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7804.html" rel="external">"Opioid use disorder: Epidemiology, clinical features, health consequences, screening, and assessment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14839.html" rel="external">"Methamphetamine use disorder: Epidemiology, clinical features, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7802.html" rel="external">"Cocaine use disorder: Epidemiology, clinical features, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7797.html" rel="external">"Cannabis use and disorder: Epidemiology, pharmacology, comorbidities, and adverse effects"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/88407.html" rel="external">"Benzodiazepine use disorder"</a>.)</p><p></p><p class="headingAnchor" id="H2142142892"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>Patients receive a substance use disorder (SUD) assessment when the possibility of an SUD has been established, for example, through screening, history, or one or more clinical findings. The purpose of a comprehensive SUD assessment is to:</p><p class="bulletIndent1"><span class="glyph">●</span>Determine the type and severity of a patient’s substance use</p><p class="bulletIndent1"><span class="glyph">●</span>Diagnose substance use disorder(s) or other conditions if present</p><p class="bulletIndent1"><span class="glyph">●</span>Understand the patient’s perception of their condition and readiness to change</p><p class="bulletIndent1"><span class="glyph">●</span>Identify comorbid psychiatric and medical conditions</p><p class="bulletIndent1"><span class="glyph">●</span>Identify barriers and facilitators to reducing substance use</p><p class="bulletIndent1"><span class="glyph">●</span>Inform the development of a plan for treatment if needed</p><p></p><p>In contrast to screening, which identifies patients at higher risk for substance use consequences, assessment is a lengthier and more complex process with the aim of reaching a diagnosis and informing treatment. Screening patients for alcohol and other drug use is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/14843.html" rel="external">"Screening for unhealthy use of alcohol and other drugs in primary care"</a>.)</p><p>Information about a patient’s substance use and its consequences should be obtained from various sources including the patient, family members, prior medical records, and clinical observation. When multiple sources of information are available, they should be compared to evaluate the accuracy of patient self-report.</p><p class="headingAnchor" id="H1429311593"><span class="h1">SUBSTANCE USE</span></p><p class="headingAnchor" id="H2509711790"><span class="h2">Type, frequency, and amount</span><span class="headingEndMark"> — </span>An initial assessment should establish which substance(s) are or have been used. Unhealthy use of one substance increases the likelihood of unhealthy use of other substances [<a href="#rid5">5,6</a>]; thus assessment should include querying about all the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) classes of substances. In a nonjudgmental fashion and to establish some level of comfort for the patient, it is typically best to first ask about socially accepted substances and progress to illicit substances. A reasonable order might be:</p><p class="bulletIndent1"><span class="glyph">●</span>Caffeine, tobacco/nicotine, alcohol. (See  <a class="medical medical_review" href="/z/d/html/5369.html" rel="external">"Benefits and risks of caffeine and caffeinated beverages", section on 'Caffeine dependence, abuse, and withdrawal'</a> and  <a class="medical medical_review" href="/z/d/html/7809.html" rel="external">"Risky drinking and alcohol use disorder: Epidemiology, clinical features, adverse consequences, screening, and assessment"</a> and  <a class="medical medical_review" href="/z/d/html/16706.html" rel="external">"Benefits and consequences of smoking cessation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prescription medications misuse (eg, opioids, sedative/hypnotics, stimulants). (See  <a class="medical medical_review" href="/z/d/html/15236.html" rel="external">"Prescription drug misuse: Epidemiology, prevention, identification, and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Marijuana – Consider medical use and misuse (as one does for prescription medications) and legal status locally along with other DSM-5-TR criteria for cannabis use disorder. (See  <a class="medical medical_review" href="/z/d/html/7797.html" rel="external">"Cannabis use and disorder: Epidemiology, pharmacology, comorbidities, and adverse effects"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Illicit drugs – Stimulants including cocaine, opioids including heroin, hallucinogens, and inhalants. (See  <a class="medical medical_review" href="/z/d/html/14839.html" rel="external">"Methamphetamine use disorder: Epidemiology, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/7802.html" rel="external">"Cocaine use disorder: Epidemiology, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/7804.html" rel="external">"Opioid use disorder: Epidemiology, clinical features, health consequences, screening, and assessment"</a> and  <a class="medical medical_review" href="/z/d/html/317.html" rel="external">"Intoxication from LSD and other common hallucinogens"</a>.)</p><p></p><p>For each substance, a few questions that determine ever used, pattern of use, last use, recent frequency (eg, once or twice a week, daily), and some indication of quantity should provide enough information to determine whether or not to assess for a substance use disorder for that particular substance. Since it is impossible to list every addictive substance a patient might be using, it is useful to ask about use of any other substances like those above (eg, novel psychoactive substances, synthetic cannabinoids, “bath salts,” and others).</p><p>Risk thresholds for alcohol in the United States as defined by the National Institute on Alcohol Abuse and Alcoholism are [<a href="#rid7">7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Males (under 65): Five or more standard drinks (ie, 12 grams of ethanol, the amount generally found in 1.5 oz of 80 proof liquor, 5 oz of wine, and 12 oz of beer) in a day or more than 14 drinks per week on average.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Females and males over 65: Four or more standard 12 gram drinks in a day or more than seven drinks in a week on average.</p><p></p><p>Similar risk thresholds have not been established for gender minority populations. There are no agreed upon definitions for unhealthy use of substances other than alcohol. For some substances, any use is considered unhealthy. For instance, any cocaine or methamphetamine use increases one’s risk of cardiac events.</p><p>Quantification is:</p><p class="bulletIndent1"><span class="glyph">●</span>Easier for tobacco (eg, number of cigarettes) and alcohol (eg, number of standard drinks) than for other drugs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Names and doses of prescription drugs may be identifiable from pictures or marking.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other substances may be purchased in more idiosyncratic quantities or may vary in potency, which is often unknown. Amount of money spent on a daily/weekly/monthly basis for drugs may help to quantify use.</p><p></p><p>Regardless of amounts, one should proceed with a comprehensive assessment in certain circumstances. Examples of such circumstances include individual drinking any amount of alcohol despite awareness of compromised liver function, pregnancy, and potential interactions with prescribed medications (eg, alcohol and benzodiazepines).</p><p class="headingAnchor" id="H1026912038"><span class="h3">History of prior substance use disorder, treatment</span><span class="headingEndMark"> — </span>If an individual has a history of SUD, evaluate participation in mutual-help groups, such as Alcoholics Anonymous or Narcotics Anonymous, and past substance use disorder treatment episodes.</p><p class="headingAnchor" id="H378362558"><span class="h2">Route of administration</span><span class="headingEndMark"> — </span>The current route of drug administration should be identified:</p><p class="bulletIndent1"><span class="glyph">●</span>Oral – Drinking, swallowing pills</p><p class="bulletIndent1"><span class="glyph">●</span>Smoking</p><p class="bulletIndent1"><span class="glyph">●</span>Intranasal inhalation (eg, "snorting" or "sniffing")</p><p class="bulletIndent1"><span class="glyph">●</span>Subcutaneous injection (eg, "skin popping”)</p><p class="bulletIndent1"><span class="glyph">●</span>Intramuscular injection (eg “muscling”)</p><p class="bulletIndent1"><span class="glyph">●</span>Intravenous injection (eg, "shooting up")</p><p></p><p>Route of administration has value in suggesting risks of medical problems (eg, perforated sinus from intranasal intake or infectious disease from injection). Associated behaviors, such as needle sharing, can increase risks of disease.</p><p>More invasive routes of delivery such as injection can be indicative of a more severe disorder [<a href="#rid6">6</a>]. For instance, research indicates that among people who use heroin, those who inject have more severe SUD than those who inhale. (See <a class="local">'General medical'</a> below.)</p><p class="headingAnchor" id="H2367010852"><span class="h2">Overdose history</span><span class="headingEndMark"> — </span>Drug overdoses in the United States are driven largely by synthetic opioids (ie, illicitly manufactured <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a> or fentanyl analogs) [<a href="#rid8">8</a>] and to lesser extent psychostimulants and cocaine, most often with concurrent involvement of synthetic opioids [<a href="#rid9">9</a>]. Use of synthetic opioids with other drugs can be inadvertent as products may be adulterated. Overdose is more likely in individuals who have an opioid use disorder. Moreover, it is important to assess overdose history as a prior overdose is associated with increased likelihood in the following year of a subsequent fatal or nonfatal overdose [<a href="#rid10">10,11</a>].</p><p class="headingAnchor" id="H1358701324"><span class="h1">MENTAL HEALTH</span><span class="headingEndMark"> — </span>The co-occurrence of mental health and substance use disorders (SUDs) is well documented [<a href="#rid12">12</a>]. For this reason, it is important for clinicians to conduct a comprehensive mental health history and evaluation to identify past and current concurrent psychiatric disorders and treatment.</p><p>Patients with SUDs are at higher risk of experiencing comorbid:</p><p class="bulletIndent1"><span class="glyph">●</span>Depressive disorders</p><p class="bulletIndent1"><span class="glyph">●</span>Bipolar disorder</p><p class="bulletIndent1"><span class="glyph">●</span>Anxiety disorders</p><p class="bulletIndent1"><span class="glyph">●</span>Posttraumatic stress disorder</p><p class="bulletIndent1"><span class="glyph">●</span>Eating disorders</p><p class="bulletIndent1"><span class="glyph">●</span>Schizophrenia</p><p class="bulletIndent1"><span class="glyph">●</span>Attention deficit hyperactivity disorder</p><p></p><p>SUD risk is elevated among individuals with personality disorders, especially borderline personality disorder and antisocial personality disorder [<a href="#rid13">13</a>].</p><p>Patients who are actively going through withdrawal may present with anxiety, agitation, sleep disturbances, and behavioral changes. Specific withdrawal symptoms vary by substance as does timing of withdrawal.</p><p>Patients may present with psychosis resulting from the ingestion of prescribed stimulants, alcohol, cocaine, phencyclidine and other hallucinogens, or methamphetamines, or from withdrawal from alcohol or sedative/hypnotic drugs such as barbiturates or benzodiazepines. Patients should be evaluated for suicidal or homicidal ideation.</p><p class="headingAnchor" id="H2601507882"><span class="h2">Mental status examination</span><span class="headingEndMark"> — </span>A mental status examination should be performed that includes the evaluation of:</p><p class="bulletIndent1"><span class="glyph">●</span>General appearance</p><p class="bulletIndent1"><span class="glyph">●</span>Behavior and interaction</p><p class="bulletIndent1"><span class="glyph">●</span>Speech and voice</p><p class="bulletIndent1"><span class="glyph">●</span>Motor activity</p><p class="bulletIndent1"><span class="glyph">●</span>Mood and affect</p><p class="bulletIndent1"><span class="glyph">●</span>Perceptions</p><p class="bulletIndent1"><span class="glyph">●</span>Thought process</p><p class="bulletIndent1"><span class="glyph">●</span>Thought content (suicidal or homicidal ideation, hallucinations, delusions)</p><p class="bulletIndent1"><span class="glyph">●</span>Insight</p><p class="bulletIndent1"><span class="glyph">●</span>Judgement</p><p class="bulletIndent1"><span class="glyph">●</span>Cognitive functioning</p><p></p><p>Findings from a mental status examination typically would be unremarkable except in cases of current intoxication or withdrawal, when the patient is actively psychotic, and when chronic substance use has resulted in impaired cognitive function and/or dementia.</p><p>The presence of a psychiatric disorder or symptoms should alert the clinician to the possibility of an SUD, as patients who have these disorders are more likely to use substances than those who do not. When comorbid substance use and psychiatric disorders are present, individuals are often more clinically severe and difficult to treat relative to those who have either type of disorder alone [<a href="#rid14">14</a>]. As such, this information is critical in the development of a comprehensive treatment plan.</p><p class="headingAnchor" id="H1535317242"><span class="h1">GENERAL MEDICAL</span><span class="headingEndMark"> — </span>Substance use can be associated with compromised functioning in virtually every system of the body [<a href="#rid15">15-17</a>]. Medical conditions may develop as a result of the toxicity of the substance, route of administration, and high-risk behaviors in which the patient engages (eg, needle sharing, unprotected sexual encounters, poor hygiene).</p><p class="headingAnchor" id="H1873037721"><span class="h2">Physical examination and medical history</span><span class="headingEndMark"> — </span>During the physical examination, the clinician should be alert to physical indicators of substance use including: </p><p class="bulletIndent1"><span class="glyph">●</span>Poor personal hygiene.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Significant weight loss or weight gain.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Signs of injection drug use including scars at injection sites (so-called “track marks”) on the skin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Signs of drug inhalation including atrophy of the nasal mucosa and perforation of the nasal septum.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of acute intoxication or withdrawal (eg, slurred speech, unsteady gait, pinpoint pupils, bizarre or atypical behavior, changes in level of arousal [agitation or sedation], tachycardia, conjunctival injection, sweating, watery eyes, runny nose).</p><p></p><p>Medical conditions that can result from and may serve as indicators of substance use include:</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiovascular problems such as hypertension, cardiomyopathy, endocarditis, and heart failure. (See  <a class="medical medical_review" href="/z/d/html/2784.html" rel="external">"Cardiovascular benefits and risks of moderate alcohol consumption", section on 'Effect of alcohol on cardiovascular risk'</a> and  <a class="medical medical_review" href="/z/d/html/4953.html" rel="external">"Clinical manifestations, diagnosis, and management of the cardiovascular complications of cocaine abuse"</a> and  <a class="medical medical_review" href="/z/d/html/2149.html" rel="external">"Right-sided native valve infective endocarditis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serious gastrointestinal and renal problems such as pancreatitis, cirrhosis, chronic liver disease, kidney failure, hepatitis B, and hepatitis C.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Central nervous system issues such as dementia, memory and attention impairments, intraparenchymal hemorrhage, cerebral vasculitis, ischemic events and strokes, and traumatic brain injury. (See  <a class="medical medical_review" href="/z/d/html/4840.html" rel="external">"Overview of the chronic neurologic complications of alcohol"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary problems such as bronchospasm, chronic obstructive lung disease, pulmonary edema, pneumonia, hypersensitivity pneumonitis, barotrauma, undifferentiated hemoptysis, and tuberculosis. (See  <a class="medical medical_review" href="/z/d/html/4343.html" rel="external">"Pulmonary complications of cocaine use"</a> and  <a class="medical medical_review" href="/z/d/html/4337.html" rel="external">"Overview of pulmonary disease in people who inject drugs"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anemia and bone marrow hypofunction. (See  <a class="medical medical_review" href="/z/d/html/7151.html" rel="external">"Hematologic complications of alcohol use"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sexually transmitted infections such as HIV, syphilis, gonorrhea, and genital warts. (See  <a class="medical medical_review" href="/z/d/html/7595.html" rel="external">"Prevention of sexually transmitted infections", section on 'Sexual health assessment'</a> and  <a class="medical medical_review" href="/z/d/html/7596.html" rel="external">"Screening for sexually transmitted infections"</a> and  <a class="medical medical_review" href="/z/d/html/3725.html" rel="external">"Substance use disorder in patients with HIV"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bacterial infections including methicillin-resistant S. aureus. (See  <a class="medical medical_review" href="/z/d/html/2135.html" rel="external">"Clinical manifestations of Staphylococcus aureus infection in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy and birth complications. (See  <a class="medical medical_review" href="/z/d/html/4799.html" rel="external">"Substance use during pregnancy: Screening and prenatal care"</a>.)</p><p></p><p>The specific medical conditions vary by the substance(s) used. In addition to evaluating presenting symptomatology, a comprehensive medical history should be taken.</p><p>Following a positive screen for unhealthy substance use or upon suspicion of a substance use disorder, clinicians should conduct a thorough review of the patient’s medical history, current symptomatology, and physical examination results to identify any physical symptoms of substance use, as well as comorbid health conditions resulting from substance use. The identification of comorbid medical conditions is a critical part in developing a treatment plan as they may impede recovery from substance use disorder [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H2997906588"><span class="h2">Laboratory tests</span><span class="headingEndMark"> — </span>Although laboratory tests of biologic samples (eg, urine, blood, sweat, hair, saliva, breath) have limited utility in making a substance use disorder diagnosis specifically, they can be used to detect recent drug use, and patients are more likely to answer questions related to use more honestly if an objective measure has been used. However, laboratory tests do not provide information on the frequency or intensity of use. For this reason, they may be more useful for monitoring abstinence repeatedly over time than for one-time assessment.</p><p>Basic biologic screens for addictive drugs used across the United States test for five drugs: amphetamine, cocaine, cannabis, some opioids, and phencyclidine. Many basic drug screens used in Australia, New Zealand, and much of the European Union and Asia omit phencyclidine but include tests for benzodiazepines and a wider range of opioids. Other drugs that may be tested for include barbiturates, methamphetamine, and synthetic opioids. Many widely used substances are not detected by routine addictive drug screening tests used in many locales, including alcohol (which can be detected by measuring ethyl glucuronide), synthetic cannabinoids, synthetic cathinones ("bath salts"); synthetic opioids, such as <a class="drug drug_general" data-topicid="9608" href="/z/d/drug information/9608.html" rel="external">meperidine</a>, <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a>, and <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">fentanyl</a>; plant-derived substances such as hallucinogenic mushrooms; and other synthesized substances such as lysergic acid diethylamide. (See  <a class="medical medical_review" href="/z/d/html/13846.html" rel="external">"Testing for drugs of abuse (DOAs)"</a>.)</p><p>Urine drug screens are the most widely used type of test as they are inexpensive, easy to administer, and noninvasive. They can identify when there is a detectable concentration of the substance, but have limited utility to detect use other than recent. A table describes the period of detection for urine screens for common drug classes  (<a class="graphic graphic_table graphicRef58181" href="/z/d/graphic/58181.html" rel="external">table 1</a>). For instance, the window of detection for amphetamines and cocaine is generally two to three days, while moderate to heavy marijuana use can be detected for up to one month. Blood toxicology tests, while accurate for detecting recent use, are used less frequently as they are more costly, less immediate, and more invasive than urine tests. Blood and breath testing (the latter providing immediate results) can inform the extent of intoxication or at least the amount used, and can be useful with injured, cognitively impaired and unconscious patients.</p><p>Several laboratory tests have been used to help identify excessive substance use and/or systemic damage and to monitor response to treatment over time. These are described in topics addressing specific classes of substances. (See  <a class="medical medical_review" href="/z/d/html/7809.html" rel="external">"Risky drinking and alcohol use disorder: Epidemiology, clinical features, adverse consequences, screening, and assessment"</a>.)</p><p>Except in emergency situations, permission for conducting a urine drug screen should be obtained from patients, as testing for illegal drugs without a person’s consent may represent a violation of their civil rights. Requirements regarding notification and permission vary by jurisdiction [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H3654243859"><span class="h1">FAMILY HISTORY</span><span class="headingEndMark"> — </span>A family history of substance use disorder (SUD) has been shown to be a risk factor for the development of an SUD [<a href="#rid20">20,21</a>]. [<a href="#rid22">22</a>]. Heritability estimates range from [<a href="#rid23">23-27</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>50 to 70 percent for alcohol use disorder</p><p class="bulletIndent1"><span class="glyph">●</span>From 34 to 78 percent for cannabis use disorder</p><p class="bulletIndent1"><span class="glyph">●</span>42 to 79 percent for cocaine use disorder</p><p class="bulletIndent1"><span class="glyph">●</span>23 to 54 percent for opioid use disorder </p><p></p><p>Family environments in which a parent or primary caregiver has an SUD are associated with higher rates of physical and sexual abuse and trauma, poor parenting skills, and poor quality parent-child interactions, all of which are risk factors for SUDs [<a href="#rid28">28,29</a>]. </p><p class="headingAnchor" id="H1436783100"><span class="h1">SOCIAL HISTORY</span><span class="headingEndMark"> — </span>A patient’s social history can provide information about risk factors for unhealthy substance use and the impact of substance use on the patient’s role functioning [<a href="#rid30">30</a>].</p><p>Risk factors for substance use include:</p><p class="bulletIndent1"><span class="glyph">●</span>A romantic partner with a substance use disorder (SUD)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Friends who have SUDs</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Living in a community characterized by poverty, violence, and/or high alcohol and other drug availability</p><p></p><p>Identification of these risk factors can be achieved by conducting a comprehensive evaluation of the patient’s living environment.</p><p>Social roles and relationships are often compromised by the development of an SUD. Individuals who have an SUD often experience the following negative social events:</p><p class="bulletIndent1"><span class="glyph">●</span>Disrupted familial and social relationships</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Failure to fulfill responsibilities at school or work (eg, loss of job, poor grades in school)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Legal involvement (eg, arrests for disorderly conduct, driving under the influence, theft)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Financial problems</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Violent behavior</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Child abuse/neglect</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Engagement in high-risk sexual behaviors (eg, multiple partners, unprotected sexual intercourse)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Failure to engage in activities that were once enjoyable</p><p></p><p>In addition to signaling the presence of an SUD, identification of these problems can inform the development of a treatment plan that includes necessary ancillary services (eg, employment services, legal services, parenting classes).</p><p>Engaging family members in the treatment process can improve the likelihood of positive outcomes for individuals who have an SUD.</p><p class="headingAnchor" id="H3107677312"><span class="h1">ASSESSMENT/DIAGNOSIS</span><span class="headingEndMark"> — </span>Diagnosis of a substance use disorder (SUD) was revised with the transition from DSM-IV to DSM-5 [<a href="#rid31">31</a>]. Replacing the two DSM-IV diagnoses of substance abuse and dependence is a single diagnosis, SUD, named by the type of substance involved (eg, alcohol use disorder or cannabis use disorder) and a specifier indicating severity. (See <a class="local">'Severity'</a> below.)</p><p>The assessment process can elicit strong feelings in the patient. It can be a positive cathartic and insightful experience and/or feel invasive and stressful. It is best conducted in a respectful, supportive and nonjudgmental manner that is responsive to the patient's needs and values. Such a patient centered approach may lead to improved treatment response.</p><p class="headingAnchor" id="H4135196361"><span class="h2">DSM-5-TR diagnostic criteria</span><span class="headingEndMark"> — </span>DSM-5-TR diagnostic criteria for SUD are described below [<a href="#rid32">32</a>].</p><p>A problematic pattern of use leading to clinically significant impairment or distress is manifested by two or more of the following within a 12-month period: </p><p class="bulletIndent1"><span class="glyph">●</span>1. Often taken in larger amounts or over a longer period than was intended.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>2. A persistent desire or unsuccessful efforts to cut down or control use.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>3. A great deal of time is spent in activities necessary to obtain, use, or recover from the substance’s effects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>4. Craving or a strong desire or urge to use the substance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>5. Recurrent use resulting in a failure to fulfill major role obligations at work, school, or home.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>6. Continued use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by its effects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>7. Important social, occupational, or recreational activities are given up or reduced because of use.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>8. Recurrent use in situations in which it is physically hazardous.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>9. Continued use despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>10. Tolerance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>11. Withdrawal.</p><p></p><p>Preoccupation with use is often demonstrated by giving up previously important activities, increasing the time spent in activities related to substance use, and using more frequently or for longer amounts of time than planned. Consumption may continue despite the continued existence or worsening of problems caused by substance use. In applying criteria on consequences and behaviors associated with use, it is important to include alcohol-related blackouts, and impulsive sexual behavior.</p><p class="headingAnchor" id="H2212527798"><span class="h3">Severity</span><span class="headingEndMark"> — </span>Alcohol and drug symptom profiles appear to vary along a severity dimension. DSM-5-TR severity specifiers mild, moderate, and severe are based on the number of diagnostic criteria met by the patient at the time of diagnosis:</p><p class="bulletIndent1"><span class="glyph">●</span>Mild – Two to three criteria</p><p class="bulletIndent1"><span class="glyph">●</span>Moderate – Four to five criteria</p><p class="bulletIndent1"><span class="glyph">●</span>Severe – Six or more criteria</p><p></p><p>Healthcare coding and billing in the United States is based on the International Classification of Diseases (ICD). DSM-5 and ICD criteria for a substance use disorder are very similar, but ICD require a minimum of three criteria instead of two. The ICD diagnoses of “harmful use” require only substance related physical or psychological harm [<a href="#rid33">33</a>].</p><p>Most published clinical trials of SUD treatment studied patients diagnosed with DSM-IV disorders. Applying these results to patients diagnosed with DSM-5-TR SUD is imprecise, but the most closely comparable groups are:</p><p class="bulletIndent1"><span class="glyph">●</span>Substance abuse – Mild subtype of SUD</p><p class="bulletIndent1"><span class="glyph">●</span>Substance dependence – Moderate to severe subtype of SUD</p><p></p><p class="headingAnchor" id="H881752129"><span class="h3">Diagnostic tools</span><span class="headingEndMark"> — </span>To diagnosis SUDs in routine clinical practice, a clinical interview is generally used to identify which DSM-5-TR diagnostic criteria are or are not met. Structured diagnostic instruments, developed to facilitate reliable and valid diagnoses for research, as well as semistructured tools, can be relatively lengthy and require training to administer; nonetheless, they can be useful in clinical practice in some specialized settings. The range of options include:</p><p class="bulletIndent1"><span class="glyph">●</span>Fully structured instruments – They generally provide a script for the assessor to follow, specify questions that should be asked, provide response codes, and identify types of probes that the interviewer should use (eg, Composite International Diagnostic Interview – Alcohol and Substance Abuse Modules) [<a href="#rid34">34-37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A relatively short structured diagnostic interview is the Mini International Neuropsychiatric Interview. It can be administered in approximately 15 minutes and assesses the 17 most common disorders in mental health including alcohol dependence and the dependence on the nonalcoholic substance causing the biggest problems [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Semistructured interviews – These instruments list questions to be read verbatim, but they allow the interviewer to add follow-up queries based on their clinical interpretation of the interviewee’s initial response (eg, Structured Clinical Interview for DSM, Alcohol and Drug Modules) [<a href="#rid39">39-41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>DSM criteria checklist – Making and documenting SUD diagnoses can also be done using a checklist that addresses each criterion for each substance under consideration. This can help assure that all diagnostic criteria are covered for all targeted substances. To increase diagnostic sensitivity and confidence, the interviewer should explore the symptoms that could meet criteria.</p><p></p><p class="headingAnchor" id="H2093732361"><span class="h2">Multidimensional assessment</span><span class="headingEndMark"> — </span>Making specific SUD diagnoses is part of a comprehensive assessment; so is ascertaining biopsychosocial context, readiness to change, and consequences and goals. The choice to conduct a multidimensional assessment beyond diagnosing an SUD is guided by facility constraints (eg, resources, time) and the clinical goal.</p><p class="bulletIndent1"><span class="glyph">●</span>When the goal is referral to a behavioral health practitioner or specialty SUD treatment, the diagnostic results, any additional substance use assessment results (eg, pattern of use, consequences, urine drug screening results), and relevant general medical, mental health, family/social history information are adequate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When on-site treatment is planned, a comprehensive assessment can identify affected life areas and issues relevant to treatment, as well as confirm appropriateness of level of care.</p><p></p><p>The assessment can be conducted by a nonclinician behavioral health specialist or other ancillary medical personnel (if available) for clinician review.</p><p>While general medical, mental health, family/social history information is supportive, it is not a substitute for a systematic multidimensional assessment. The domains include:</p><p class="bulletIndent1"><span class="glyph">●</span>Alcohol and other drugs (eg, pattern of use, treatment history; consequences, acute intoxication/withdrawal potential, continued use/problem potential)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Employment/financial</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Illegal activity and justice involvement</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Family/social and living environment</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Biomedical conditions and complications</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Emotional, behavioral, or cognitive conditions and complications</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Readiness to change/treatment readiness</p><p></p><p>The multidimensional approach to the assessment of SUD patients has been supported and validated by the use of the Addiction Severity Index (ASI) for over 35 years [<a href="#rid42">42-44</a>] and adopted in practice [<a href="#rid45">45</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>The ASI is a semistructured interview that can be conducted by trained interviewers. It has self-administered and computerized versions [<a href="#rid46">46,47</a>]. The ASI assesses current and lifetime functioning in life domains that affect or are affected by SUD and are relevant to the appropriate treatment of SUD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The Global Appraisal of Individual Needs (GAIN; [<a href="#rid48">48</a>]) is another rather comprehensive biopsychosocial assessment for SUD patients. The GAIN has the reported advantage of being appropriate for adolescents as well as adults.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adolescent-specific biopsychosocial assessment instruments have been developed and tested solely for youth (eg, Comprehensive Adolescent Severity Inventory [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patient placement criteria (PPC) developed by the American Society of Addiction Medicine (ASAM) are another multidimensional assessment instrument, this one developed to determine a patient’s appropriate level of care along a continuum of SUD treatment services [<a href="#rid50">50,51</a>]. It is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7799.html" rel="external">"Substance use disorders: Determining appropriate level of care for treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The GAIN was developed to map onto the ASAM PPC; the ASI can substantially inform placement [<a href="#rid52">52</a>]. Expanded versions of the ASI have been developed to assist in making ASAM PPC level of care decisions [<a href="#rid52">52,53</a>]. A comprehensive tool for this purpose is CONTINUUM: The ASAM Criteria Decision Engine – a computer-guided, semistructured interview.</p><p></p><p>These multidimensional instruments (which all take about an hour to administer) along with the diagnostic results, any additional substance use assessment results (eg, pattern of use, consequences, urine drug screening results), and relevant general medical, mental health, family/social history provide the necessary information to make an initial patient placement and comprehensive treatment plan and to serve as a baseline from which to monitor progress.</p><p>There is a good deal of overlap in content among these instruments. To shorten the length of assessment, minimize patient burden, and maximize the amount and quality of useful information obtained, redundant questions can be identified and eliminated.</p><p>Other instruments assess individual subjects in more depth than the multidimensional instruments do (eg, readiness to change [<a href="#rid54">54</a>] and personal consequences [<a href="#rid55">55</a>]). (See  <a class="medical medical_review" href="/z/d/html/16752.html" rel="external">"Substance use disorders: Motivational interviewing", section on 'Readiness to change'</a>.)</p><p class="headingAnchor" id="H1569074631"><span class="h2">Progress monitoring</span><span class="headingEndMark"> — </span>Monitoring the clinical status of SUD patients on a regular basis during treatment has been recommended by the Institute of Medicine since 2006 [<a href="#rid56">56</a>]. Progress monitoring improves outcomes in mental health treatment [<a href="#rid57">57,58</a>] and there are demonstrations of various approaches that have been successfully used as part of SUD treatment [<a href="#rid59">59</a>]. (See  <a class="medical medical_review" href="/z/d/html/16754.html" rel="external">"Continuing care for addiction: Components and efficacy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Treatment attendance and urine drug screen results have been the mainstay of progress monitoring in SUD treatment and are recommended [<a href="#rid60">60-62</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For those noted to have an elevated gamma-glutamyltransferase or carbohydrate deficient transferrin at the beginning of treatment, repeated testing can be used to track the patient’s progress in treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who were evaluated using the Short Inventory of Problems, serial administration of the instrument along with repeated questions about the drug-use frequency or alcohol-use quantity can help monitor progress.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Calls have been made for additional measures that provide a more multidimensional picture of patient functioning and that support measurement based care [<a href="#rid56">56,63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are several brief instruments that have demonstrated reliability and validity with SUD patients that can be used for such purposes (eg, Brief Addiction Monitor [<a href="#rid64">64,65</a>]; Treatment Outcome Profile [<a href="#rid66">66</a>]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>More intensive and extensive monitoring can be conducted with follow-up versions of the ASI, GAIN, or CONTINUUM.</p><p></p><p class="headingAnchor" id="H1931080634"><span class="h2">Withdrawal potential</span><span class="headingEndMark"> — </span>Withdrawal is included in the diagnostic criteria for SUD, and withdrawal potential is a dimension in the ASAM criteria. As such, they are included in the diagnostic and comprehensive assessments, respectively. Withdrawal has different symptoms and manifestations, risks, and treatments and treatment implications across substances.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/105686.html" rel="external">"Opioid withdrawal: Clinical features, assessment, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/108527.html" rel="external">"Alcohol withdrawal: Epidemiology, clinical manifestations, course, assessment, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/314.html" rel="external">"Benzodiazepine poisoning"</a> and  <a class="medical medical_review" href="/z/d/html/141183.html" rel="external">"Benzodiazepine withdrawal"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7801.html" rel="external">"Alcohol withdrawal: Ambulatory management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/323.html" rel="external">"Management of moderate and severe alcohol withdrawal syndromes"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7808.html" rel="external">"Opioid withdrawal: Medically supervised withdrawal during treatment for opioid use disorder"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/114326.html" rel="external">"Cannabis withdrawal: Epidemiology, clinical features, diagnosis, and treatment"</a>.)</p><p></p><p class="headingAnchor" id="H426697396"><span class="h1">APPLICATION TO TREATMENT PLANNING</span><span class="headingEndMark"> — </span>The data gathered from a thorough substance use disorder assessment informs the clinician and patient’s development of a treatment plan, including:</p><p class="bulletIndent1"><span class="glyph">●</span>General substance use disorder (SUD) issues</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The extent of the problem or disorder – (See  <a class="medical medical_review" href="/z/d/html/7809.html" rel="external">"Risky drinking and alcohol use disorder: Epidemiology, clinical features, adverse consequences, screening, and assessment"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The patient’s readiness for treatment – (See  <a class="medical medical_review" href="/z/d/html/16752.html" rel="external">"Substance use disorders: Motivational interviewing", section on 'Readiness to change'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The intensity, level, and sequencing of care – (See  <a class="medical medical_review" href="/z/d/html/16754.html" rel="external">"Continuing care for addiction: Components and efficacy"</a> and  <a class="medical medical_review" href="/z/d/html/7799.html" rel="external">"Substance use disorders: Determining appropriate level of care for treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Substance-specific treatment</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Opioids</strong> – (See  <a class="medical medical_review" href="/z/d/html/108803.html" rel="external">"Opioid use disorder: Treatment overview"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Alcohol</strong> – (See  <a class="medical medical_review" href="/z/d/html/14832.html" rel="external">"Brief intervention for unhealthy alcohol and other drug use: Efficacy, adverse effects, and administration"</a> and  <a class="medical medical_review" href="/z/d/html/7800.html" rel="external">"Alcohol use disorder: Pharmacologic management"</a> and  <a class="medical medical_review" href="/z/d/html/7810.html" rel="external">"Alcohol use disorder: Psychosocial management"</a> and  <a class="medical medical_review" href="/z/d/html/7805.html" rel="external">"Identification and management of unhealthy alcohol use in the perioperative period"</a> and  <a class="medical medical_review" href="/z/d/html/14614.html" rel="external">"Nutritional status in patients with sustained heavy alcohol use"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stimulants</strong> – (See  <a class="medical medical_review" href="/z/d/html/106878.html" rel="external">"Stimulant use disorder: Treatment overview"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cannabis</strong> – (See  <a class="medical medical_review" href="/z/d/html/7796.html" rel="external">"Cannabis use disorder: Clinical features, screening, diagnosis, and treatment"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Multiple substances</strong> – (See  <a class="medical medical_review" href="/z/d/html/15236.html" rel="external">"Prescription drug misuse: Epidemiology, prevention, identification, and management"</a> and  <a class="medical medical_review" href="/z/d/html/7570.html" rel="external">"Evidence-based approach to prevention"</a> and  <a class="medical medical_review" href="/z/d/html/103550.html" rel="external">"Substance use disorders: Training, implementation, and efficacy of treatment with contingency management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other treatment issues informed by assessment findings include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Social issues (eg, homeless) may inform level of care assignment. (See <a class="local">'Social history'</a> above and  <a class="medical medical_review" href="/z/d/html/7799.html" rel="external">"Substance use disorders: Determining appropriate level of care for treatment"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A patient with a severe SUD may require multiple treatment modalities. (See  <a class="medical medical_review" href="/z/d/html/16754.html" rel="external">"Continuing care for addiction: Components and efficacy"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A patient with an SUD and a disabling psychiatric disorder may benefit from referral to an addiction psychiatrist or coordinated or integrated addiction and psychiatric care, if available.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A patient with an SUD and serious medical conditions may benefit from referral to coordinated or integrated addiction and medical care, if available.</p><p></p><p class="headingAnchor" id="H1391466239"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Substance use disorders (SUDs) </strong>– We undertake a thorough substance use assessment including a detailed inventory of the type, amount, frequency, and consequences of a patient’s substance use. We assess the individual’s perception of their use and readiness to change. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type, frequency, and amount </strong>– For each substance, principally, tobacco/nicotine, alcohol, prescription medications and illicit drugs (opioids, stimulants, cannabis, sedative/hypnotics), we ask the patient a few questions that determine ever used, pattern of use, last use, recent frequency (eg, once or twice a week, daily), and an indication of quantity. We use this information to determine whether or not to assess for an SUD for that particular substance. (See <a class="local">'Type, frequency, and amount'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mental health </strong>– The co-occurrence of mental health and SUDs is well documented. We conduct a comprehensive mental health history and evaluation to identify past and current psychiatric disorders and treatment. (See <a class="local">'Mental health'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medical effects</strong> – Substance use can be associated with compromised functioning in virtually every system of the body. Medical conditions may develop as a result of the toxicity of the substance, route of administration, and high-risk behaviors in which the patient engages (eg, needle sharing, unprotected sexual encounters, poor hygiene). (See <a class="local">'General medical'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory tests</strong> – Although laboratory tests of biologic samples (eg, urine, blood, sweat, hair, saliva, breath) have limited utility in making an SUD diagnosis specifically, we often use them to detect recent drug use. We believe patients are more likely to answer questions related to use more honestly if an objective measure has been used. (See <a class="local">'Laboratory tests'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Family history </strong>– A family history of SUDs has been shown to be a risk factor, with genetic and environmental components, for the development of an SUD. Family environments in which a parent or primary caregiver has an SUD are associated with higher rates of physical and sexual abuse and trauma, poor parenting skills, and poor quality parent-child interactions, all of which are risk factors for SUDs. (See <a class="local">'Family history'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Social history</strong> – Individuals who have SUD often have disrupted familial and social relationships, unfulfilled responsibilities at school or work, problems related to finances, the legal system, raising children, violence, and engaging in high-risk behaviors. They often to engage in activities that were once enjoyable. (See <a class="local">'Social history'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – We use a clinical interview to identify if an individual meets American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) diagnostic criteria. Structured diagnostic instruments, developed to facilitate reliable and valid diagnoses for research, along with semistructured tools can be relatively lengthy and require training to administer; nonetheless, they can be useful in clinical practice in some specialized settings. (See <a class="local">'DSM-5-TR diagnostic criteria'</a> above.)</p><p></p><p class="headingAnchor" id="H3880104019"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Michael F Weaver, MD, and Margaret A E Jarvis, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: Results from the 2020 National Survey on Drug Use and Health. HHS Publication No. PEP21-07-0, Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administratio; Department of Health and Human Services, Rockville, MD 2021.</li><li class="breakAll">Substance Abuse and Mental Health Services Administration. Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits. HHS Publication No. (SMA) 13-4760, DAWN Series D-39, Substance Abuse and Mental Health Services Administration; Department of Health and Human Services, Rockville, MD 2013.</li><li><a class="nounderline abstract_t">Suen LW, Makam AN, Snyder HR, et al. National Prevalence of Alcohol and Other Substance Use Disorders Among Emergency Department Visits and Hospitalizations: NHAMCS 2014-2018. J Gen Intern Med 2022; 37:2420.</a></li><li class="breakAll">Ahmad FB, Rossen LM, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics; Department of Health and Human Services, 2021.</li><li class="breakAll">Center for Behavioral Health Statistics and Quality. Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health (HHS Publication No. SMA 15-4927, NSDUH Series H-50). 2015. http://www.samhsa.gov/data/sites/default/files/NSDUH-FRR1-2014/NSDUH-FRR1-2014.pdf (Accessed on May 31, 2016).</li><li><a class="nounderline abstract_t">Gossop M, Griffiths P, Powis B, Strang J. Severity of dependence and route of administration of heroin, cocaine and amphetamines. Br J Addict 1992; 87:1527.</a></li><li class="breakAll">National Institute on Alcohol Abuse and Alcoholism: Helping Patients Who Drink Too Much: A Clinician’s Guide. 2005 Edition. http://www.niaaa.nih.gov/guide (Accessed on May 31, 2016).</li><li><a class="nounderline abstract_t">Mattson CL, Tanz LJ, Quinn K, et al. Trends and Geographic Patterns in Drug and Synthetic Opioid Overdose Deaths - United States, 2013-2019. MMWR Morb Mortal Wkly Rep 2021; 70:202.</a></li><li><a class="nounderline abstract_t">Hedegaard H, Miniño AM, Warner M. Co-involvement of Opioids in Drug Overdose Deaths Involving Cocaine and Psychostimulants. NCHS Data Brief 2021; :1.</a></li><li><a class="nounderline abstract_t">Olfson M, Wall M, Wang S, et al. Risks of fatal opioid overdose during the first year following nonfatal overdose. Drug Alcohol Depend 2018; 190:112.</a></li><li><a class="nounderline abstract_t">Karmali RN, Ray GT, Rubinstein AL, et al. The role of substance use disorders in experiencing a repeat opioid overdose, and substance use treatment patterns among patients with a non-fatal opioid overdose. Drug Alcohol Depend 2020; 209:107923.</a></li><li><a class="nounderline abstract_t">Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62:617.</a></li><li><a class="nounderline abstract_t">Skodol AE, Oldham JM, Gallaher PE. Axis II comorbidity of substance use disorders among patients referred for treatment of personality disorders. Am J Psychiatry 1999; 156:733.</a></li><li class="breakAll">Nunes EV, Selzer J, Levounis P, Davies CA. Substance Dependence and Co-Occurring Psychiatric Disorders, Civic Research Institute, Kingston 2010.</li><li class="breakAll">National Institute on Drug Abuse. Medical Consequences of Drug Abuse. https://www.drugabuse.gov/related-topics/medical-consequences-drug-abuse (Accessed on May 31, 2016).</li><li class="breakAll">Saitz R. Medical and surgical complications of addiction. In: Principles of Addiction Medicine, ASAM, New York 2014. p.1027.</li><li><a class="nounderline abstract_t">Stein MD. Medical consequences of substance abuse. Psychiatr Clin North Am 1999; 22:351.</a></li><li><a class="nounderline abstract_t">Mertens JR, Flisher AJ, Satre DD, Weisner CM. The role of medical conditions and primary care services in 5-year substance use outcomes among chemical dependency treatment patients. Drug Alcohol Depend 2008; 98:45.</a></li><li class="breakAll">Substance Abuse and Mental Health Services Administration. Clinical Drug Testing in Primary Care, Technical Assistance Publication (TAP) 32. HHS Publication No. (SMA) 12-4668, Substance Abuse and Mental Health Services Administration; Department of Health and Human Services, Rockville, MD 2012.</li><li><a class="nounderline abstract_t">Kendler KS, Davis CG, Kessler RC. The familial aggregation of common psychiatric and substance use disorders in the National Comorbidity Survey: a family history study. Br J Psychiatry 1997; 170:541.</a></li><li><a class="nounderline abstract_t">Orford J, Velleman R. Offspring of parents with drinking problems: drinking and drug-taking as young adults. Br J Addict 1990; 85:779.</a></li><li><a class="nounderline abstract_t">Merikangas KR, Stolar M, Stevens DE, et al. Familial transmission of substance use disorders. Arch Gen Psychiatry 1998; 55:973.</a></li><li><a class="nounderline abstract_t">Agrawal A, Lynskey MT. The genetic epidemiology of cannabis use, abuse and dependence. Addiction 2006; 101:801.</a></li><li><a class="nounderline abstract_t">Kendler KS, Karkowski LM, Neale MC, Prescott CA. Illicit psychoactive substance use, heavy use, abuse, and dependence in a US population-based sample of male twins. Arch Gen Psychiatry 2000; 57:261.</a></li><li><a class="nounderline abstract_t">Tsuang MT, Bar JL, Harley RM, Lyons MJ. The Harvard Twin Study of Substance Abuse: what we have learned. Harv Rev Psychiatry 2001; 9:267.</a></li><li><a class="nounderline abstract_t">van den Bree MB, Johnson EO, Neale MC, Pickens RW. Genetic and environmental influences on drug use and abuse/dependence in male and female twins. Drug Alcohol Depend 1998; 52:231.</a></li><li><a class="nounderline abstract_t">Tsuang MT, Lyons MJ, Meyer JM, et al. Co-occurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities. Arch Gen Psychiatry 1998; 55:967.</a></li><li><a class="nounderline abstract_t">Dube SR, Felitti VJ, Dong M, et al. Childhood abuse, neglect, and household dysfunction and the risk of illicit drug use: the adverse childhood experiences study. Pediatrics 2003; 111:564.</a></li><li><a class="nounderline abstract_t">Kumpfer KL, Bluth B. Parent/child transactional processes predictive of resilience or vulnerability to "substance abuse disorders". Subst Use Misuse 2004; 39:671.</a></li><li class="breakAll">Substance Abuse and Mental Health Service Administration. Risk and protective factors. Published October 2015. http://www.samhsa.gov/capt/practicing-effective-prevention/prevention-behavioral-health/risk-protective-factors (Accessed on May 31, 2016).</li><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual, 5th ed, American Psychiatric Publishing, Arlington 2013.</li><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), Washington, DC 2022.</li><li class="breakAll">Woody GE, Cacciola J. Diagnosis and Classification of DSM-IV-TR and ICD-10. In: Lowinson and Ruiz’s Substance Abuse:  A Comprehensive Textbook, 5th ed, Ruiz P, Strain EC (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.117.</li><li><a class="nounderline abstract_t">Cottler LB, Robins LN, Helzer JE. The reliability of the CIDI-SAM: a comprehensive substance abuse interview. Br J Addict 1989; 84:801.</a></li><li><a class="nounderline abstract_t">Haro JM, Arbabzadeh-Bouchez S, Brugha TS, et al. Concordance of the Composite International Diagnostic Interview Version 3.0 (CIDI 3.0) with standardized clinical assessments in the WHO World Mental Health surveys. Int J Methods Psychiatr Res 2006; 15:167.</a></li><li><a class="nounderline abstract_t">Horton J, Compton W, Cottler LB. Reliability of substance use disorder diagnoses among African-Americans and Caucasians. Drug Alcohol Depend 2000; 57:203.</a></li><li><a class="nounderline abstract_t">Wittchen HU. Reliability and validity studies of the WHO--Composite International Diagnostic Interview (CIDI): a critical review. J Psychiatr Res 1994; 28:57.</a></li><li><a class="nounderline abstract_t">Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59 Suppl 20:22.</a></li><li><a class="nounderline abstract_t">Kranzler HR, Kadden RM, Babor TF, et al. Validity of the SCID in substance abuse patients. Addiction 1996; 91:859.</a></li><li><a class="nounderline abstract_t">Steiner JL, Tebes JK, Sledge WH, Walker ML. A comparison of the structured clinical interview for DSM-III-R and clinical diagnoses. J Nerv Ment Dis 1995; 183:365.</a></li><li><a class="nounderline abstract_t">Williams JB, Gibbon M, First MB, et al. The Structured Clinical Interview for DSM-III-R (SCID). II. Multisite test-retest reliability. Arch Gen Psychiatry 1992; 49:630.</a></li><li><a class="nounderline abstract_t">Cacciola JS, Alterman AI, Habing B, McLellan AT. Recent status scores for version 6 of the Addiction Severity Index (ASI-6). Addiction 2011; 106:1588.</a></li><li><a class="nounderline abstract_t">McLellan AT, Cacciola JC, Alterman AI, et al. The Addiction Severity Index at 25: origins, contributions and transitions. Am J Addict 2006; 15:113.</a></li><li><a class="nounderline abstract_t">Denis CM, Cacciola JS, Alterman AI. Addiction Severity Index (ASI) summary scores: comparison of the Recent Status Scores of the ASI-6 and the Composite Scores of the ASI-5. J Subst Abuse Treat 2013; 45:444.</a></li><li class="breakAll">The ASAM criteria :treatment for addictive, substance-related, and co-occurring conditions, Mee-Lee D (Ed), American Society of Addiction Medicine, Chevy Chase 2013.</li><li><a class="nounderline abstract_t">Butler SF, Budman SH, Goldman RJ, et al. Initial validation of a computer-administered Addiction Severity Index: the ASI-MV. Psychol Addict Behav 2001; 15:4.</a></li><li><a class="nounderline abstract_t">Rosen CS, Henson BR, Finney JW, Moos RH. Consistency of self-administered and interview-based Addiction Severity Index composite scores. Addiction 2000; 95:419.</a></li><li class="breakAll">Dennis ML. Global Appraisal of Individual Needs (GAIN): A standardized biopsychosocial assessment tool, Chestnut Health Systems, Bloomington 2010.</li><li><a class="nounderline abstract_t">Meyers K, Hagan TA, McDermott P, et al. Factor structure of the Comprehensive Adolescent Severity Inventory (CASI): results of reliability, validity, and generalizability analyses. Am J Drug Alcohol Abuse 2006; 32:287.</a></li><li class="breakAll">American Society of Addiction Medicine, ASAM. Terminology related to the spectrum of unhealthy substance use. Published July 2013. http://www.asam.org/docs/default-source/public-policy-statements/1-terminology-spectrum-sud-7-13.pdf?sfvrsn=2 (Accessed on May 31, 2016).</li><li class="breakAll">The ASAM Criteria: Treatment Criteria for Addictive, Substance-Related, and Co-Occurring Conditions, 3rd ed., Mee-Lee D, Shulman GD, Fishman MJ, et al (Eds), The Change Company, Carson City, NV 2013.</li><li><a class="nounderline abstract_t">Camilleri AC, Cacciola JS, Jenson MR. Comparison of two ASI-based standardized patient placement approaches. J Addict Dis 2012; 31:118.</a></li><li><a class="nounderline abstract_t">Stallvik M, Gastfriend DR, Nordahl HM. Matching patients with substance use disorder to optimal level of care with the ASAM Criteria software. J Subst Use 2014; 20:389.</a></li><li><a class="nounderline abstract_t">Miller WR, Tonigan SJ. Assessing drinkers' motivation for change: The Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES). Psychol Addict Behav 1996; 10:81.</a></li><li><a class="nounderline abstract_t">Alterman AI, Cacciola JS, Ivey MA, et al. Reliability and validity of the alcohol short index of problems and a newly constructed drug short index of problems. J Stud Alcohol Drugs 2009; 70:304.</a></li><li class="breakAll">Institute of Medicine. Improving the quality of health care for mental and substance use conditions: quality chasm series, The National Academies Press, Washington DC 2006.</li><li><a class="nounderline abstract_t">Knaup C, Koesters M, Schoefer D, et al. Effect of feedback of treatment outcome in specialist mental healthcare: meta-analysis. Br J Psychiatry 2009; 195:15.</a></li><li><a class="nounderline abstract_t">Poston JM, Hanson WE. Meta-analysis of psychological assessment as a therapeutic intervention. Psychol Assess 2010; 22:203.</a></li><li><a class="nounderline abstract_t">Goodman JD, McKay JR, DePhillipis D. Progress monitoring in mental health and addiction: a means of improving care. Prof Psychol Res Pr 2013; 44:231.</a></li><li><a class="nounderline abstract_t">McLellan AT, Skipper GS, Campbell M, DuPont RL. Five year outcomes in a cohort study of physicians treated for substance use disorders in the United States. BMJ 2008; 337:a2038.</a></li><li><a class="nounderline abstract_t">Marlowe DB, Festinger DS, Dugosh KL, et al. Adaptive Programming Improves Outcomes in Drug Court: An Experimental Trial. Crim Justice Behav 2012; 39:514.</a></li><li><a class="nounderline abstract_t">Brooner RK, Kidorf M. Using behavioral reinforcement to improve methadone treatment participation. Sci Pract Perspect 2002; 1:38.</a></li><li><a class="nounderline abstract_t">McLellan AT, McKay JR, Forman R, et al. Reconsidering the evaluation of addiction treatment: from retrospective follow-up to concurrent recovery monitoring. Addiction 2005; 100:447.</a></li><li><a class="nounderline abstract_t">Cacciola JS, Alterman AI, Dephilippis D, et al. Development and initial evaluation of the Brief Addiction Monitor (BAM). J Subst Abuse Treat 2013; 44:256.</a></li><li><a class="nounderline abstract_t">Hallinan S, Gaddy M, Ghosh A, Burgen E. Factor structure and measurement invariance of the Revised Brief Addiction Monitor. Psychol Assess 2021; 33:273.</a></li><li><a class="nounderline abstract_t">Marsden J, Farrell M, Bradbury C, et al. Development of the Treatment Outcomes Profile. Addiction 2008; 103:1450.</a></li></ol></div><div id="topicVersionRevision">Topic 7807 Version 34.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: Results from the 2020 National Survey on Drug Use and Health. HHS Publication No. PEP21-07-0, Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administratio; Department of Health and Human Services, Rockville, MD 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Substance Abuse and Mental Health Services Administration. Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits. HHS Publication No. (SMA) 13-4760, DAWN Series D-39, Substance Abuse and Mental Health Services Administration; Department of Health and Human Services, Rockville, MD 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34518978" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : National Prevalence of Alcohol and Other Substance Use Disorders Among Emergency Department Visits and Hospitalizations: NHAMCS 2014-2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34518978" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : National Prevalence of Alcohol and Other Substance Use Disorders Among Emergency Department Visits and Hospitalizations: NHAMCS 2014-2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34518978" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : National Prevalence of Alcohol and Other Substance Use Disorders Among Emergency Department Visits and Hospitalizations: NHAMCS 2014-2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1458032" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Severity of dependence and route of administration of heroin, cocaine and amphetamines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1458032" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Severity of dependence and route of administration of heroin, cocaine and amphetamines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33571180" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Trends and Geographic Patterns in Drug and Synthetic Opioid Overdose Deaths - United States, 2013-2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33814035" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Co-involvement of Opioids in Drug Overdose Deaths Involving Cocaine and Psychostimulants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30005310" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Risks of fatal opioid overdose during the first year following nonfatal overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32126455" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The role of substance use disorders in experiencing a repeat opioid overdose, and substance use treatment patterns among patients with a non-fatal opioid overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15939839" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10327906" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Axis II comorbidity of substance use disorders among patients referred for treatment of personality disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10327906" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Axis II comorbidity of substance use disorders among patients referred for treatment of personality disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10327906" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Axis II comorbidity of substance use disorders among patients referred for treatment of personality disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10327906" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Axis II comorbidity of substance use disorders among patients referred for treatment of personality disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10385938" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Medical consequences of substance abuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18571875" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The role of medical conditions and primary care services in 5-year substance use outcomes among chemical dependency treatment patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18571875" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The role of medical conditions and primary care services in 5-year substance use outcomes among chemical dependency treatment patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9330021" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The familial aggregation of common psychiatric and substance use disorders in the National Comorbidity Survey: a family history study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2378995" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Offspring of parents with drinking problems: drinking and drug-taking as young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9819065" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Familial transmission of substance use disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16696624" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The genetic epidemiology of cannabis use, abuse and dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10711912" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Illicit psychoactive substance use, heavy use, abuse, and dependence in a US population-based sample of male twins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11600486" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The Harvard Twin Study of Substance Abuse: what we have learned.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9839149" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Genetic and environmental influences on drug use and abuse/dependence in male and female twins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9819064" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Co-occurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12612237" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Childhood abuse, neglect, and household dysfunction and the risk of illicit drug use: the adverse childhood experiences study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15202804" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Parent/child transactional processes predictive of resilience or vulnerability to "substance abuse disorders".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15202804" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Parent/child transactional processes predictive of resilience or vulnerability to "substance abuse disorders".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15202804" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Parent/child transactional processes predictive of resilience or vulnerability to "substance abuse disorders".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15202804" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Parent/child transactional processes predictive of resilience or vulnerability to "substance abuse disorders".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15202804" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Parent/child transactional processes predictive of resilience or vulnerability to "substance abuse disorders".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2758153" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The reliability of the CIDI-SAM: a comprehensive substance abuse interview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17266013" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Concordance of the Composite International Diagnostic Interview Version 3.0 (CIDI 3.0) with standardized clinical assessments in the WHO World Mental Health surveys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10661671" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Reliability of substance use disorder diagnoses among African-Americans and Caucasians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8064641" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Reliability and validity studies of the WHO--Composite International Diagnostic Interview (CIDI): a critical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9881538" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8696248" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Validity of the SCID in substance abuse patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7798084" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A comparison of the structured clinical interview for DSM-III-R and clinical diagnoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1637253" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The Structured Clinical Interview for DSM-III-R (SCID). II. Multisite test-retest reliability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21545666" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Recent status scores for version 6 of the Addiction Severity Index (ASI-6).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16595348" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The Addiction Severity Index at 25: origins, contributions and transitions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23886822" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Addiction Severity Index (ASI) summary scores: comparison of the Recent Status Scores of the ASI-6 and the Composite Scores of the ASI-5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23886822" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Addiction Severity Index (ASI) summary scores: comparison of the Recent Status Scores of the ASI-6 and the Composite Scores of the ASI-5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11255937" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Initial validation of a computer-administered Addiction Severity Index: the ASI-MV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10795362" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Consistency of self-administered and interview-based Addiction Severity Index composite scores.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10795362" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Consistency of self-administered and interview-based Addiction Severity Index composite scores.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16864465" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Factor structure of the Comprehensive Adolescent Severity Inventory (CASI): results of reliability, validity, and generalizability analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16864465" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Factor structure of the Comprehensive Adolescent Severity Inventory (CASI): results of reliability, validity, and generalizability analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16864465" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Factor structure of the Comprehensive Adolescent Severity Inventory (CASI): results of reliability, validity, and generalizability analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22540434" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Comparison of two ASI-based standardized patient placement approaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Matching patients with substance use disorder to optimal level of care with the ASAM Criteria software</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Assessing drinkers' motivation for change: The Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19261243" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Reliability and validity of the alcohol short index of problems and a newly constructed drug short index of problems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19261243" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Reliability and validity of the alcohol short index of problems and a newly constructed drug short index of problems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19567889" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Effect of feedback of treatment outcome in specialist mental healthcare: meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20528048" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Meta-analysis of psychological assessment as a therapeutic intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Progress monitoring in mental health and addiction: a means of improving care</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18984632" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Five year outcomes in a cohort study of physicians treated for substance use disorders in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22923854" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Adaptive Programming Improves Outcomes in Drug Court: An Experimental Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18567965" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Using behavioral reinforcement to improve methadone treatment participation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15784059" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Reconsidering the evaluation of addiction treatment: from retrospective follow-up to concurrent recovery monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22898042" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Development and initial evaluation of the Brief Addiction Monitor (BAM).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33090827" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Factor structure and measurement invariance of the Revised Brief Addiction Monitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18783500" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Development of the Treatment Outcomes Profile.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
